ImmunityBio, Inc. (DUS:26CA) Financings
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock and warrants Announced: about US$80M · Piper Sandler & Co. Dealers: Piper Sandler & Co. (lead) Use of proceeds: Further working capital and support for ongoing business operations | Jul 25, 2025 |
| Registered direct offering of common stock and warrants Announced: about US$75M · warrants for the purchase of additional shares of common stock; if fully exercised,… Buyers: single institutional investor Use of proceeds: Working capital and ongoing business operations | Apr 8, 2025 |
| Public offering of common stock Update: about US$100M · US$3 a share · Jefferies +4 Dealers: Jefferies (co-lead), Piper Sandler (co-lead), BTIG (co-lead), H.C. Wainwright & Co. (co-lead), D. Boral Capital Use of proceeds: Commercialization of ANKTIVA for bladder cancer, trials in BCG-naive NMIBC and NSCLC, R&D, working capital and general corporate purposes | Dec 11, 2024 |